Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D67AKN
|
|||
| Drug Name |
PXL-770
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-alcoholic fatty liver disease [ICD-11: DB92; ICD-10: K76.0; ICD-9: 571.8] | Phase 2 | [1] | |
| Company |
Poxel SA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03763877) A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Poxel SA. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.